Web Analytics

Thought Leadership

  • Studies On Adaptive Trials In Rare Cancer

    Rare cancers account for up to 20% of new cancer cases and Innovative Medicinal Products (InMP) are required to address this high unmet medical need. Adaptive trials may be an alternative to large randomized controlled trials for InMP development to target rare cancer patients.

    Our research with

    KOL

    s &

    HCP

    s have helped inform studies about the perceived value of adaptive trials and surrogate endpoints for

    clinical

    decisions. Oncologists rated evidence from adaptive

    clinical

    trials with as a high value and importance for

    clinical

    decision processes as randomised controlled trials. The results have been presented at ASCO, ESMO, and published in Frontiers In Oncology.

    https://www.annalsofoncology.org/article/S0923-7534(20)40656-8/fulltext
    https://doi.org/10.1016/j.annonc.2020.08.660
    https://www.frontiersin.org/articles/10.3389/fonc.2021.636561/full

    If you are unable to access the abstract, please do contact us for a summary.

  • Developing An Insights Framework

    Why is an Insight framework important? What are the components of an Insight framework? How can technology support a framework?

    In our MAPS (Medical Affairs Professional Society) webinar we address these three important questions - the why, the what, the how - to help organisations connect all

    stakeholders

    , maximise the value of the Insights they collect, and creative an environment that leads to truly actionable Insights.

    We also address why “Insights” covers more than just Field MSL Insights and extends to include insights from all Medical Affairs interactions, Advisory Boards, Congress interactions, R&D interaction, and even Medical Information.

    https://medicalaffairs.org/building-a-framework-to-manage-msl-insights/

    If you are unable to access the webinar, please do contact us for a summary.

  • Developing An Integrated End-To-End / Contract-To-Pay HCP Workflow

    Developing an integrated E2E / C2P

    HCP

    management workflow has tremendous benefits - dramatically increase efficiency, decrease risk, reduce costs, and seriously improve governance.
    Creating an effective, streamlined, and compliant

    HCP

    management process is challenging and complicated.
    Our presentation addresses all the important variables and workflows to consider when developing an end-to-end process – creating events, budgets, needs assessment, approvals,

    HCP

    selection,

    HCP

    approvals,

    HCP

    screening, conflict management, cross-border transactions, contracting, FMV data, CAPS management, privacy consent management, execution, event close management, expense management,

    HCP

    payments, financial integration, transparency reporting, and much more!

    https://transparency2020.eventfinity.co/directories/33971/attendee/327200117

    If you are unable to access the webinar, please do contact us for a summary.

  • Unfeasibly Prolific Authors

    Using publication history from PubMed to help identify

    Experts

    or assess an individual

    KOL

    s work?
    Then you should probably be aware of our work to identify people (and

    KOL

    s) with “unfeasibly prolific” authorship!

    Our work has been presented at the International Congress on Peer Review and Biomedical Publication, the International Society for Medical Publication Professionals, and published in PeerJ.

    When measuring productivity, one should be alert not only to unproductive researchers but also to unfeasibly prolific ones. It's also worth considering the true value of “publication metrics” when trying to identify or characterise

    KOL

    s/

    Experts

    .

    "Too much of a good thing? An observational study of prolific authors”, by Elizabeth Wager PhD (Sideview), Sanjay Singhvi MBA (System Analytic), Sabine Kleinert MRCP (The Lancet).

    https://peerj.com/articles/1154/

    We use such research to help guide our clients on the value of different metrics in the context of identifying and mapping

    KOL

    s.
  • KOL Terminology

    External

    Experts

    , Therapeutic Area

    Experts

    , Scientific Content

    Experts

    , Thought Leaders,

    Experts

    – what do we call

    KOL

    s if we can't/won't/shouldn't call them “

    KOL

    s”?
    We asked

    KOL

    s and clients, and received an amazing response - 199 responses from

    KOL

    s, and 185 responses from Pharma Professionals across the US and Europe.

    62% of KOLs believe the term “KOL” should be replaced, but there was great debate about what should it be replaced with, with no clear winner – in fact there were 24 different terms suggested by KOLs!

    There was however a significant and very vocal group (from Pharma and

    KOL

    s) that advocated the continued use of the terms

    KOL

    , for many different reasons.
    A massive 77% did however agree that all companies and

    stakeholders

    work towards one universal transparent replacement for the term "

    KOL

    " going forwards, rather than different companies labelling them differently.
  • Deep Dives

    We often create non-promotional educational content for our clients that want to learn more about specific areas. A few current examples are given below:

    Continually engaging and interacting with

    Key Opinion Leaders

    (KOLs) ,

    Experts

    , and

    HCP

    s for a variety of reasons is an essential part of Medical Affairs and Commercial activities. To learn more about how a Virtual Advisory Board (VAB) can help with this, please visit virtual-advisory-boards.html

    KOL Management

    is a broad term that refers to the complete life cycle of identifying, mapping, segmenting, planning, engaging, and interacting with

    KOL

    s. From beginning to end. To learn more about key questions to ask at every step of the

    KOL

    cycle to ensure compliance and true scientific value, please visit KOLmanagement.html
    With all roads leading to digital, the collaboration between

    HCP

    s and pharma companies can be managed very effectively through an

    HCP

    Portal. To learn more about how an

    HCP

    Portal can support the entire

    HCP

    workflow, please visit https://systemanalytic.com/HCP-portal.html

    Please contact us for additional content on topics of interest.

Services & Tools

Please tick the services and digital tools that you’re interested in and we’ll get back to you with further information on them.
Digital Platforms Services General



GO!

Your submission has been received!

We will get back to you soon.

Ok